newsfilter
← Latest News
GlobeNewswire·

Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events Patients Completing Treatment with Emricasan had a Complete Resolution of the Symptoms Most Commonly Associated in Mild COVID-19 At Day 7 Continuing to Day 45 SAN DIEGO, J